New Delhi, Jan. 8 -- The Indian Pharmaceutical Market (IPM) concluded 2025 with a valuation of approximately Rs 2,40,672 crore, reflecting a value growth of 8.1 per cent. According to the Pharmarack Indian Pharma Industry Performance report, IPM is likely to maintain the same growth range of 7.8-8.1% in 2026 as well.

This realistic scenario aligns with current market realities, where value growth remains robust despite fluctuating volume trends. The data indicates that the industry continued to show resilience, with all primary therapy segments maintaining positive value trajectories as of December 2025.

The growth in the market is primarily driven by three key levers: price increases, new product launches, and volume adjustments. In th...